Stifel Maintains Buy on Astrana Health, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Chris O'Cull maintains a Buy rating on Astrana Health (NASDAQ:ASTH) and raises the price target from $45 to $48.
June 27, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Chris O'Cull maintains a Buy rating on Astrana Health and raises the price target from $45 to $48.
The Buy rating and increased price target from a reputable analyst at Stifel is likely to positively impact investor sentiment and drive short-term price appreciation for Astrana Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100